0	5	C/EBP	C/EBP	NNP
6	10	beta	beta	NN
11	13	in	in	IN
14	24	rheumatoid	rheumatoid	JJ
25	34	arthritis	arthritis	NN
34	35	:	:	:
36	47	correlation	correlation	NN
48	52	with	with	IN
53	65	inflammation	inflammation	NN
65	66	,	,	,
67	70	not	not	RB
71	78	disease	disease	NN
79	90	specificity	specificity	NN
90	91	.	.	.

93	103	Rheumatoid	rheumatoid	JJ
104	113	arthritis	arthritis	NN
114	122	synovial	synovial	JJ
123	129	tissue	tissue	NN
130	133	was	be	VBD
134	142	examined	examine	VBN
143	146	and	and	CC
147	155	compared	compare	VBN
156	160	with	with	IN
161	175	osteoarthritis	osteoarthritis	NN
176	182	tissue	tissue	NN
183	186	for	for	IN
187	190	the	the	DT
191	199	presence	presence	NN
200	202	of	of	IN
203	206	the	the	DT
207	214	nuclear	nuclear	JJ
215	228	transcription	transcription	NN
229	235	factor	factor	NN
236	241	C/EBP	C/EBP	NNP
242	246	beta	beta	NN
247	248	(	(	(
248	257	NF-IL-6).	NF-IL-6).	NNP
258	261	The	the	DT
262	268	region	region	NN
269	270	(	(	(
270	276	lining	lining	JJ
277	279	or	or	CC
280	289	sublining	sublining	JJ
289	290	)	)	)
290	291	,	,	,
292	296	cell	cell	NN
297	301	type	type	NN
301	302	,	,	,
303	306	and	and	CC
307	318	subcellular	subcellular	JJ
319	331	distribution	distribution	NN
332	333	(	(	(
333	344	cytoplasmic	cytoplasmic	JJ
345	347	or	or	CC
348	355	nuclear	nuclear	JJ
355	356	)	)	)
357	359	of	of	IN
360	363	the	the	DT
364	374	expression	expression	NN
375	377	of	of	IN
378	383	C/EBP	C/EBP	NNP
384	388	beta	beta	NN
389	392	was	be	VBD
393	406	characterized	characterize	VBN
406	407	.	.	.

408	418	Rheumatoid	rheumatoid	JJ
419	428	arthritis	arthritis	NN
429	437	synovial	synovial	JJ
438	443	fluid	fluid	NN
444	447	and	and	CC
448	453	blood	blood	NN
454	457	and	and	CC
458	464	normal	normal	JJ
465	475	peripheral	peripheral	JJ
476	481	blood	blood	NN
482	486	were	be	VBD
487	491	also	also	RB
492	500	examined	examine	VBN
500	501	.	.	.

502	507	C/EBP	C/EBP	NNP
508	512	beta	beta	NN
513	516	was	be	VBD
517	525	detected	detect	VBN
526	528	in	in	IN
529	532	the	the	DT
533	541	synovial	synovial	JJ
542	548	lining	lining	NN
549	552	and	and	CC
553	555	in	in	IN
556	565	sublining	sublining	JJ
566	571	cells	cell	NNS
572	574	of	of	IN
575	583	synovial	synovial	JJ
584	590	tissue	tissue	NN
591	595	from	from	IN
596	604	patients	patient	NNS
605	609	with	with	IN
610	614	both	both	CC
615	625	rheumatoid	rheumatoid	JJ
626	629	and	and	CC
630	644	osteoarthritis	osteoarthritis	NN
644	645	.	.	.

646	647	A	a	DT
648	659	significant	significant	JJ
660	661	(	(	(
661	662	P	p	NN
663	664	<	<	JJR
665	670	0.001	0.001	CD
671	674	and	and	CC
675	676	<	<	JJR
677	681	0.05	0.05	CD
681	682	,	,	,
683	695	respectively	respectively	RB
695	696	)	)	)
697	705	increase	increase	NN
706	708	in	in	IN
709	712	the	the	DT
713	723	percentage	percentage	NN
724	726	of	of	IN
727	732	cells	cell	NNS
733	737	with	with	IN
738	745	nuclear	nuclear	JJ
746	754	staining	staining	NN
755	758	was	be	VBD
759	763	seen	see	VBN
764	766	in	in	IN
767	770	the	the	DT
771	777	lining	lining	JJ
778	783	layer	layer	NN
783	784	,	,	,
785	793	compared	compare	VBN
794	796	to	to	TO
797	802	cells	cell	NNS
803	805	in	in	IN
806	809	the	the	DT
810	819	sublining	sublining	JJ
820	826	region	region	NN
826	827	,	,	,
828	830	in	in	IN
831	841	rheumatoid	rheumatoid	NN
842	845	and	and	CC
846	860	osteoarthritis	osteoarthritis	NN
860	861	.	.	.

862	864	In	in	IN
865	869	both	both	DT
870	878	diseases	disease	NNS
879	880	a	a	DT
881	887	strong	strong	JJ
888	899	correlation	correlation	NN
900	901	(	(	(
901	902	r	r	NN
903	904	=	=	SYM
905	909	0.79	0.79	CD
909	910	,	,	,
911	912	P	p	NN
913	914	<	<	SYM
915	920	0.001	0.001	CD
920	921	)	)	)
922	925	was	be	VBD
926	934	observed	observe	VBN
935	942	between	between	IN
943	946	the	the	DT
947	957	percentage	percentage	NN
958	960	of	of	IN
961	966	cells	cell	NNS
967	969	in	in	IN
970	973	the	the	DT
974	982	synovial	synovial	JJ
983	989	lining	lining	NN
990	994	that	that	WDT
995	999	were	be	VBD
1000	1008	positive	positive	JJ
1009	1012	for	for	IN
1013	1020	nuclear	nuclear	JJ
1021	1026	C/EBP	C/EBP	NNP
1027	1031	beta	beta	NN
1032	1035	and	and	CC
1036	1042	lining	lining	JJ
1043	1047	cell	cell	NN
1048	1053	depth	depth	NN
1053	1054	.	.	.

1055	1064	Two-color	two-color	JJ
1065	1085	immunohistochemistry	immunohistochemistry	NN
1086	1098	demonstrated	demonstrate	VBD
1099	1103	that	that	IN
1104	1108	both	both	CC
1109	1120	macrophages	macrophage	NNS
1121	1124	and	and	CC
1125	1140	fibroblast-like	fibroblast-like	JJ
1141	1153	synoviocytes	synoviocyte	NNS
1154	1158	were	be	VBD
1159	1167	positive	positive	JJ
1168	1171	for	for	IN
1172	1179	nuclear	nuclear	JJ
1180	1185	C/EBP	C/EBP	NNP
1186	1190	beta	beta	NN
1190	1191	.	.	.

1192	1195	The	the	DT
1196	1204	presence	presence	NN
1205	1207	of	of	IN
1208	1213	C/EBP	C/EBP	NNP
1214	1218	beta	beta	NN
1219	1222	was	be	VBD
1223	1232	confirmed	confirm	VBN
1233	1235	by	by	IN
1236	1256	immunohistochemistry	immunohistochemistry	NN
1257	1260	and	and	CC
1261	1268	Western	western	NN
1269	1273	blot	blot	NN
1274	1282	analysis	analysis	NN
1283	1287	with	with	IN
1288	1296	isolated	isolate	VBN
1297	1305	synovial	synovial	JJ
1306	1317	fibroblasts	fibroblast	NNS
1317	1318	.	.	.

1319	1326	Nuclear	nuclear	JJ
1327	1332	C/EBP	C/EBP	NNP
1333	1337	beta	beta	NN
1338	1341	was	be	VBD
1342	1346	also	also	RB
1347	1355	detected	detect	VBN
1356	1358	in	in	IN
1359	1369	rheumatoid	rheumatoid	JJ
1370	1378	synovial	synovial	JJ
1379	1384	fluid	fluid	NN
1385	1406	monocytes/macrophages	monocytes/macrophage	NNS
1406	1407	,	,	,
1408	1411	but	but	CC
1412	1415	not	not	RB
1416	1418	in	in	IN
1419	1430	lymphocytes	lymphocyte	NNS
1431	1433	or	or	CC
1434	1445	neutrophils	neutrophil	NNS
1445	1446	.	.	.

1447	1454	Western	western	NN
1455	1459	blot	blot	NN
1460	1468	analysis	analysis	NN
1469	1478	confirmed	confirm	VBD
1479	1482	the	the	DT
1483	1491	presence	presence	NN
1492	1494	of	of	IN
1495	1500	C/EBP	C/EBP	NNP
1501	1505	beta	beta	NN
1506	1508	in	in	IN
1509	1514	these	these	DT
1515	1520	cells	cell	NNS
1520	1521	.	.	.

1522	1525	The	the	DT
1526	1535	intensity	intensity	NN
1536	1538	of	of	IN
1539	1544	C/EBP	C/EBP	NNP
1545	1549	beta	beta	NN
1550	1558	staining	staining	NN
1559	1562	was	be	VBD
1563	1570	greater	great	JJR
1571	1572	(	(	(
1572	1573	P	p	NN
1574	1575	<	<	SYM
1576	1581	0.001	0.001	CD
1581	1582	)	)	)
1583	1585	in	in	IN
1586	1594	synovial	synovial	JJ
1595	1600	fluid	fluid	NN
1601	1610	monocytes	monocyte	NNS
1611	1615	than	than	IN
1616	1618	in	in	IN
1619	1624	those	those	DT
1625	1629	from	from	IN
1630	1636	normal	normal	JJ
1637	1639	or	or	CC
1640	1650	rheumatoid	rheumatoid	JJ
1651	1661	peripheral	peripheral	JJ
1662	1667	blood	blood	NN
1667	1668	.	.	.

1669	1671	In	in	IN
1672	1682	conclusion	conclusion	NN
1682	1683	,	,	,
1684	1687	the	the	DT
1688	1696	enhanced	enhance	VBN
1697	1704	nuclear	nuclear	JJ
1705	1713	staining	staining	NN
1714	1717	for	for	IN
1718	1723	C/EBP	C/EBP	NNP
1724	1728	beta	beta	NN
1729	1731	in	in	IN
1732	1735	the	the	DT
1736	1744	synovial	synovial	JJ
1745	1751	lining	lining	NN
1751	1752	,	,	,
1753	1761	compared	compare	VBN
1762	1764	to	to	TO
1765	1768	the	the	DT
1769	1778	sublining	sublining	NN
1778	1779	,	,	,
1780	1790	suggesting	suggest	VBG
1791	1801	activation	activation	NN
1802	1804	in	in	IN
1805	1808	the	the	DT
1809	1815	lining	lining	NN
1815	1816	,	,	,
1817	1820	and	and	CC
1821	1824	the	the	DT
1825	1833	positive	positive	JJ
1834	1845	correlation	correlation	NN
1846	1848	of	of	IN
1849	1855	lining	lining	JJ
1856	1861	layer	layer	NN
1862	1867	depth	depth	NN
1868	1872	with	with	IN
1873	1876	the	the	DT
1877	1887	percentage	percentage	NN
1888	1890	of	of	IN
1891	1896	cells	cell	NNS
1897	1899	in	in	IN
1900	1903	the	the	DT
1904	1910	lining	lining	NN
1911	1919	positive	positive	JJ
1920	1923	for	for	IN
1924	1931	nuclear	nuclear	JJ
1932	1937	C/EBP	C/EBP	NNP
1938	1942	beta	beta	NN
1942	1943	,	,	,
1944	1951	suggest	suggest	VBP
1952	1953	a	a	DT
1954	1963	potential	potential	JJ
1964	1968	role	role	NN
1969	1972	for	for	IN
1973	1978	C/EBP	C/EBP	NNP
1979	1983	beta	beta	NN
1984	1986	in	in	IN
1987	1994	chronic	chronic	JJ
1995	2007	inflammation	inflammation	NN
2007	2008	.	.	.

2009	2012	The	the	DT
2013	2023	regulation	regulation	NN
2024	2026	of	of	IN
2027	2030	the	the	DT
2031	2041	production	production	NN
2042	2044	or	or	CC
2045	2053	activity	activity	NN
2054	2056	of	of	IN
2057	2062	C/EBP	C/EBP	NNP
2063	2067	beta	beta	NN
2067	2068	,	,	,
2069	2071	to	to	TO
2072	2079	inhibit	inhibit	VB
2080	2092	inflammatory	inflammatory	JJ
2093	2101	mediator	mediator	NN
2102	2112	expression	expression	NN
2113	2115	by	by	IN
2116	2124	synovial	synovial	JJ
2125	2136	macrophages	macrophage	NNS
2137	2140	and	and	CC
2141	2152	fibroblasts	fibroblast	NNS
2152	2153	,	,	,
2154	2160	offers	offer	VBZ
2161	2162	a	a	DT
2163	2168	novel	novel	JJ
2169	2177	approach	approach	NN
2178	2180	to	to	TO
2181	2192	therapeutic	therapeutic	JJ
2193	2205	intervention	intervention	NN
2205	2206	.	.	.